Literature DB >> 29372567

Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders.

B P Chumpitazi1, G L Kearns2, R J Shulman1,3.   

Abstract

BACKGROUND: Peppermint oil has been used for centuries as a treatment for gastrointestinal ailments. It has been shown to have several effects on gastrointestinal physiology relevant to clinical care and management. AIM: To review the literature on peppermint oil regarding its metabolism, effects on gastrointestinal physiology, clinical use and efficacy, and safety.
METHODS: We performed a PubMed literature search using the following terms individually or in combination: peppermint, peppermint oil, pharmacokinetics, menthol, oesophagus, stomach, small intestine, gallbladder, colon, transit, dyspepsia, nausea, abdominal pain, and irritable bowel syndrome. Full manuscripts evaluating peppermint oil that were published through 15 July 2017 were reviewed. When evaluating therapeutic indications, only randomised clinical trials were included. References from selected manuscripts were used if relevant.
RESULTS: It appears that peppermint oil may have several mechanisms of action including: smooth muscle relaxation (via calcium channel blockade or direct enteric nervous system effects); visceral sensitivity modulation (via transient receptor potential cation channels); anti-microbial effects; anti-inflammatory activity; modulation of psychosocial distress. Peppermint oil has been found to affect oesophageal, gastric, small bowel, gall-bladder, and colonic physiology. It has been used to facilitate completion of colonoscopy and endoscopic retrograde cholangiopancreatography. Placebo controlled studies support its use in irritable bowel syndrome, functional dyspepsia, childhood functional abdominal pain, and post-operative nausea. Few adverse effects have been reported in peppermint oil trials.
CONCLUSION: Peppermint oil is a natural product which affects physiology throughout the gastrointestinal tract, has been used successfully for several clinical disorders, and appears to have a good safety profile.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29372567      PMCID: PMC5814329          DOI: 10.1111/apt.14519

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  86 in total

1.  Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study.

Authors:  A Madisch; C J Heydenreich; V Wieland; R Hufnagel; J Hotz
Journal:  Arzneimittelforschung       Date:  1999-11

2.  Efficacy of peppermint oil as an antispasmodic during endoscopic retrograde cholangiopancreatography.

Authors:  Natsuyo Yamamoto; Yousuke Nakai; Naoki Sasahira; Kenji Hirano; Takeshi Tsujino; Hiroyuki Isayama; Yutaka Komatsu; Minoru Tada; Mimoru Tada; Haruhiko Yoshida; Takao Kawabe; Naoki Hiki; Michio Kaminishi; Hanzo Kurosaka; Masao Omata
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

3.  Antibacterial and antifungal activity of ten essential oils in vitro.

Authors:  S Pattnaik; V R Subramanyam; C Kole
Journal:  Microbios       Date:  1996

4.  The effect of menthol on acute experimental colitis in rats.

Authors:  Masoumeh Ghasemi-Pirbaluti; Ehsan Motaghi; Homan Bozorgi
Journal:  Eur J Pharmacol       Date:  2017-03-18       Impact factor: 4.432

5.  A systems biology approach identifies the biochemical mechanisms regulating monoterpenoid essential oil composition in peppermint.

Authors:  Rigoberto Rios-Estepa; Glenn W Turner; James M Lee; Rodney B Croteau; B Markus Lange
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Effect of essential oils on the viability and morphology of Escherichia coli (SP-11).

Authors:  S Pattnaik; V R Subramanyam; C C Rath
Journal:  Microbios       Date:  1995

7.  Does peppermint oil relieve spasm during barium enema?

Authors:  M J Sparks; P O'Sullivan; A A Herrington; S K Morcos
Journal:  Br J Radiol       Date:  1995-08       Impact factor: 3.039

8.  Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: a pharmacokinetic study.

Authors:  K W Somerville; C R Richmond; G D Bell
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

9.  Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time.

Authors:  K J Goerg; Th Spilker
Journal:  Aliment Pharmacol Ther       Date:  2003-02       Impact factor: 8.171

10.  Modulation of cognitive performance and mood by aromas of peppermint and ylang-ylang.

Authors:  Mark Moss; Steven Hewitt; Lucy Moss; Keith Wesnes
Journal:  Int J Neurosci       Date:  2008-01       Impact factor: 2.292

View more
  18 in total

1.  Impact of Peppermint Therapy on Dysphagia and Non-cardiac Chest Pain: A Pilot Study.

Authors:  Mohamed H G Khalaf; Sejal Chowdhary; B Joseph Elmunzer; Puja Sukhwani Elias; Donald Castell
Journal:  Dig Dis Sci       Date:  2019-02-15       Impact factor: 3.199

2.  New mint on the block - Fresh hope for IBS treatment?

Authors:  Radislav Nakov; Henriette Heinrich
Journal:  United European Gastroenterol J       Date:  2021-11-03       Impact factor: 4.623

3.  Study of the Mechanism of Antiemetic Effect of Lavandula angustifolia Mill. Essential Oil Based on Ca2+/CaMKII/ERK1/2 Pathway.

Authors:  Jia Li; Xiao Wang; Shining Xun; Qiuting Guo; Yao Wang; Yanzuo Jia; Wenfei Wang; Yujiao Wang; Taotao Li; Tiantian Tang; Junbo Zou; Mei Wang; Ming Yang; Fang Wang; Xiaofei Zhang; Changli Wang
Journal:  Drug Des Devel Ther       Date:  2022-07-26       Impact factor: 4.319

Review 4.  Dietary Modification for the Restoration of Gut Microbiome and Management of Symptoms in Irritable Bowel Syndrome.

Authors:  Andrew Thomas; Annie Thomas; Madeline Butler-Sanchez
Journal:  Am J Lifestyle Med       Date:  2021-05-10

5.  Essential oil nebulization in mild COVID-19(EONCO): Early phase exploratory clinical trial.

Authors:  Ramya Rathod; Ritin Mohindra; Akshay Vijayakumar; Roop Kishor Soni; Ramandeep Kaur; Ankit Kumar; Naveen Hegde; Aishwarya Anand; Swati Sharma; Vikas Suri; Kapil Goyal; Arnab Ghosh; Ashish Bhalla; Nanda Gamad; Amrit Pal Singh; Amol N Patil
Journal:  J Ayurveda Integr Med       Date:  2022-07-06

Review 6.  How to Implement the 3-Phase FODMAP Diet Into Gastroenterological Practice.

Authors:  Nessmah Sultan; Jane E Varney; Emma P Halmos; Jessica R Biesiekierski; Chu K Yao; Jane G Muir; Peter R Gibson; Caroline J Tuck
Journal:  J Neurogastroenterol Motil       Date:  2022-07-30       Impact factor: 4.725

7.  Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.

Authors:  Yuri A Saito; Ann E Almazar; Katherine E Tilkes; Rok Seon Choung; Michael D Van Norstrand; Cathy D Schleck; Alan R Zinsmeister; Nicholas J Talley
Journal:  Aliment Pharmacol Ther       Date:  2019-01-20       Impact factor: 8.171

8.  Randomised trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain.

Authors:  Robert J Shulman; Bruno P Chumpitazi; Susan M Abdel-Rahman; Uttam Garg; Salma Musaad; Gregory L Kearns
Journal:  Br J Clin Pharmacol       Date:  2021-10-19       Impact factor: 4.335

Review 9.  Diet and functional dyspepsia: Clinical correlates and therapeutic perspectives.

Authors:  Marcella Pesce; Martina Cargiolli; Sara Cassarano; Barbara Polese; Barbara De Conno; Laura Aurino; Nicola Mancino; Giovanni Sarnelli
Journal:  World J Gastroenterol       Date:  2020-02-07       Impact factor: 5.742

10.  Comparison of the Effect of Inhalation Aromatherapy with 10% and 30% Peppermint Essential Oils on the Severity of Nausea in Abdominal Surgery Patients.

Authors:  Yasin Ahmadi; Jahangir Rezaei; Mansour Rezaei; Alireza Khatony
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.